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Abstract
Background: We organized and conducted a profi-
ciency testing study (CardioOrmocheck) to evaluate
the differences in analytical performance of brain
natriuretic peptide (BNP) and N-terminal proBNP (NT-
proBNP) immunoassays.
Methods: Approximately 90 Italian laboratories were
involved in the 2005–2007 proficiency testing cycles,
while 112 laboratories took part in the 2008 cycle
(from January to May 2008). A total of 28 study sam-
ples were measured by participating laboratories for
a total of 2354 determinations.
Results: The mean total variability for BNP (50.6 %CV)
was significantly higher than that for NT-proBNP (8.4
%CV). In addition, the mean variability due to differ-
ences between-methods (46.4 %CV) comprised the
majority of the total variability for BNP. Between-
method variability for BNP comprised, on average,
84% of total variability, while the within-method vari-
ability comprised an average of 20.2 %CV. On the con-
trary, for NT-proBNP the within-method variability
(7.3 %CV) represented the majority of total variability
(average 75%), while between-method variability was
smaller (4.1 %CV). Imprecision around the cut-off
value showed marked differences among methods,
especially for BNP immunoassay methods. In addi-
tion, BNP methods were affected by large systematic
differences, for example an average 2.7-fold differ-
ence between Access and ADVIA Centaur methods,
while agreement between NT-proBNP methods was
better (an average 1.2-fold difference between Dimen-
sion and ECLIA on the Elecsys methods).
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Conclusions: This multicenter collaborative study
demonstrates that there are significant differences in
analytical characteristics and measured values among
the most popular commercial methods for BNP and
NT-proBNP. Clinicians should be very careful when
comparing results obtained by laboratories that use
different methods.
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Introduction
Cardiac natriuretic peptides, which include atrial
natriuretic peptide (ANP), brain natriuretic peptide
(BNP) and their related pro-hormones (proANP and
proBNP), constitute a complex family of peptide hor-
mones produced and secreted by the heart. ANP and
BNP are greatly increased in diseases characterized
by an expanded fluid volume, especially heart failure
(1). The active peptides, ANP and BNP, are produced
by cleavage of the COOH-terminal part of the pro-hor-
mone (proANP and pro-BNP), while the N-terminal
fragments of pro-hormone, NT-proANP and NT-
proBNP, are currently considered inactive (1, 2).
Measurement of BNP and its related-peptides is
considered a useful marker of myocardial function
(1–6), and has been recently included, along with the
ECG and radiogram of the thorax, in the first step of
the algorithm for diagnosis of heart failure as pro-
posed by the Task Force of the European Society of
Cardiology (7, 8). Recent meta-analyses (4, 5) have
confirmed that BNP and NT-proBNP assays have a
high degree of diagnostic accuracy and clinical rele-
vance in both acute and chronic heart failure. How-
ever, several studies suggest that there are significant
differences in the analytical and clinical characteris-
tics, including differences in reference ranges, deci-
sion levels and cut-off values, among immunoassays
for B-type related peptides that might allow mislead-
ing clinical interpretation (9–12).
In order to evaluate the differences in analytical per-
formance and clinical utility of the most commonly
used BNP and NT-proBNP immunoassays, a profi-
ciency testing study, based on an external quality
assessment scheme called CardioOrmocheck, was
implemented in Italy in January 2005. In this article
we report the results obtained in this multicenter
study following activity from January 2005 to May
2008.
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Table 1 Study samples: consensus mean values (mean of the measured values by all methods and laboratories) for BNP
and NT-proBNP assays, matrix material, and groups used for blood collection (healthy subjects or cardiac patients with or
without symptomatic heart failure).
Sample BNP, NT-proBNP, Matrix material Blood collection
pool/year ng/L ng/L
1/2005 6.2 100.3 Plasma-EDTA Healthy subjects
2/2005 64.8 55.7 Plasma-EDTA Cardiac patients
3/2005 23.7 72.5 Plasma-EDTA Cardiac patients
4/2005 315.8 4627 Plasma-EDTA Heart failure patients
5/2005 38.9 865.4 Plasma-EDTA Healthy subjects
4/2005 202.9 4167 Plasma-EDTA Heart failure patients
3/2005 19.2 421.6 Plasma-EDTA Healthy subjects
6/2005 273.4 12,290 Plasma-EDTA Heart failure patients
2/2006 280.1 6620 Plasma-EDTA Heart failure patients
5/2006 9.3 209.7 Plasma-Li-heparin Healthy subjects
1/2006 51.4 817.2 Plasma-EDTA Cardiac patients
2/2006 295.5 6536 Plasma-EDTA Heart failure patients
3/2006 11.7 60.5 Plasma-EDTA Healthy subjects
6/2006 109.3 4886 Plasma-Li-heparin Cardiac patients
4/2006 30.4 896.2 Plasma-EDTA Cardiac patients
1/2006 48.5 781.2 Plasma-EDTA Healthy female subjects
4/2007 67.3 2055 Plasma-EDTA Cardiac patients
5/2007 10.3 528.2 Plasma-Li-heparin Healthy subjects
1/2007 12.2 559.5 Plasma-EDTA Healthy subjects
6/2007 166.8 3763 Plasma-EDTA Heart failure patients
7/2007 115.2 2717 Plasma-EDTA Heart failure patients
7/2007 133.7 2696 Plasma-EDTA Heart failure patients
4/2007 72.7 2157 Plasma-EDTA Cardiac patients
2/2007 11.0 1059 Serum Healthy subjects
4/2007 78.1 2051 Plasma-EDTA Cardiac patients
1/2008 115.1 3272 Plasma-EDTA Heart failure patients
3/2008 12.7 1618 Plasma-EDTA Cardiac patients
2/2008 25.5 1684 Plasma-EDTA Cardiac patients
Materials and methods
Collaborative study
The CardioOrmocheck study is a proficiency testing program
for the measurement of BNP and NT-proBNP. The study was
organized in Italy in 2005 under the patronage of the Study
Group of the Cardiovascular Biomarkers of the Italian Soci-
ety of Clinical Biochemistry (SIBioC) by three accreditated
(ISO 9001 accreditation) laboratories: QUALIMED LAB srl,
working at CNR Institute of Clinical Physiology and Fonda-
zione G. Monasterio of Pisa, Department of Laboratory
Medicine, University-Hospital of Padova, and Biomedical
Research Center of Castelfranco Veneto, Italy. These labo-
ratories served in the capacity of central laboratories for the
study. On average, ;90 Italian laboratories were involved in
the testing cycle from 2005 to 2007, while 112 laboratories
took part in the 2008 cycle (from January to May 2008). The
majority (84%) of participating laboratories were Hospital
laboratories, while only 16% were private laboratories.
Sample preparation
In total, 28 study samples with different BNP and NT-proBNP
concentrations were prepared by the three central laborato-
ries (Table 1) according to the ILAC G13 guidelines. These
samples were then measured by all participating laborato-
ries for a total of 2354 determinations; some of these same
samples were analyzed repeatedly by all laboratories to eval-
uate within-laboratory variability. A summary of assay meth-
ods used to measure BNP and NT-proBNP are shown in
Table 2.
Study samples were prepared by pooling several plasma
or serum specimens to obtain a sample pool with final vol-
ume of about 100 mL and immediately frozen at –208C. Dif-
ferent sample types were used, including EDTA plasma,
Li-heparin plasma, or serum. All samples were tested to
ensure absence of HBsAg, anti-HCV, and anti-HIV. Pools
were prepared using residual serum or plasma from sam-
ples collected from apparently healthy subjects, also divided
according to gender, and patients with cardiac diseases, with
or without symptomatic heart failure. Demographic infor-
mation about the 28 study samples are shown in Table 1.
Blood samples collected from ;30 to 50 healthy subjects or
patients comprised each study sample. All study participants
gave informed consensus for use of their residual blood
samples.
Study samples were lyophilized and then sent by mail to
all participating laboratories. Lyophilization was performed
by polymed (Sambuca, Firenze, Italy) within 2 weeks after
preparation of the sample pools. Stored sample pools, were
thawed, aliquoted into ;150 vials of 0.5 mL each, and then
lyophilized. Typical temperature parameters for the lyophi-
lization process were: –458C for freezing, –208C for the pri-
mary phase, q258C for secondary phase, and –608C for
condensation. The time for each of the lyophilization steps
were ;2 h for freezing, 24–36 h for primary phase evapor-
ation, and ;18–24 h for secondary phase evaporation. The
lyophilized materials were reconstituted with 0.5 mL of dis-
tilled water prior to analysis. BNP and NT-proBNP concen-
trations in all study samples were measured prior to, and
following lyophilization, by the central laboratory (CNR Insti-
tute of Clinical Physiology in Pisa) in order to evaluate the
recovery of BNP and NT-proBNP following the lyophilization
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Table 2 Listing of BNP and NT-proBNP assay methods used by participant laboratories.
BNP assays
1. SHIONORIA BNP, Shionogi and Co, Ltd, Osaka, Japan (used by 5% of laboratories).
2. BNP for AxSYM and ARCHITECT platforms, Abbott Diagnostics, Abbott Park, IL, USA (used by 8% of laboratories).
3. BNP for Access and UniCel DxI platforms, Beckman, Beckman Coulter, Inc, Fullerton, CA, USA (used by 11% of
laboratories).
4. Triage BNP, Biosite Incorporated, San Diego, CA, USA (used by 15% of laboratories).
5. Advia Centaur BNP, Siemens Healthcare Diagnostics, Tarrytown, NY, USA (used by 14% of laboratories).
NT-proBNP assays
1. NT-proBNP for Dimension System, Siemens Healthcare Diagnostics, Tarrytown, NY, USA (used by 6%
of laboratories).
2. ECLIA proBNP assay for ELECSYS and Modular platforms, Roche Diagnostics GmbH, Mannheim, Germany (used by 27%
of laboratories).
3. NT-proBNP assay for Immulite 2500 platform, Siemens Medical Solution Diagnostics, Tarrytown, NY, USA (used by
14% of laboratories).
Table 3A Percent recovery following lyophilization in 5 plasma samples measured using the most common BNP immuno-
assay methods.
Sample ACCESS TRIAGE ADVIA AxSYM
Before, After, % Before, After, % Before, After, % Before, After, %
ng/L ng/L ng/L ng/L ng/L ng/L ng/L ng/L
1 28 16 57 7.6 5.7 75 8.9 3.6 40 27 17 63
2 51 31 61 14 7.8 57 19 8.2 43 78 46 59
3 111 78 70 28 21 77 40 29 73 145 133 92
4 289 176 61 103 57 55 111 46 41 356 137 39
5 969 714 74 374 259 69 385 242 63 1271 732 58
Mean"SD 64.6"7.1 66.6"10.1 52.0"15.1 62.2"19.1
Before, assay performed on the original plasma sample prior to lyophilization; After, assay performed on the reconstituted
plasma following lyophilization; %, percent recovery. ACCESS, Access Beckman; TRIAGE, Triage Biosite; ADVIA, ADVIA Cen-
taur Siemens; AxSYM, AxSym Abbott.
procedure, as well as the stability of BNP and NT-proBNP in
the samples.
Statistical analysis
Statistical analysis of collected data was performed by the
Department of Laboratory Medicine, CNR Institute of Clinical
Physiology. Cumulative reports were prepared and sent by
mail to each participant laboratory on a periodic basis. Par-
ticipant laboratories could also access their individual data
and cumulative reports online at http://www.ifc.cnr.it/eqas/.
Total variability was estimated by averaging the CVs cal-
culated from the results obtained on each study sample. This
variability included both systematic between-method differ-
ences and differences between each of the laboratories. The
imprecision of the different methods used by participant lab-
oratories was estimated by averaging the CVs of results for
the same study sample. Thus, the reported average CVs
used for calculation of imprecision profiles was an estimate
of the within-method and between-laboratories imprecision
that was obtained.
Results
Study samples
BNP and NT-proBNP concentrations in all plasma
pools were measured in the Laboratory of the CNR
Institute of Clinical Physiology before and after lyo-
philization. Recovery (mean"SEM) following lyophi-
lization was significantly higher (ps0.0006 by paired
t-test) for NT-proBNP (87.8%"4.4%) measured using
the ECLIA method on the Elecsys platform, than for
BNP (66.8%"4.3%) measured using the Beckman
ACCESS. Each study sample was measured at least
four times using the ECLIA method for NT-proBNP
and the ACCESS for BNP. We compared the recovery
of BNP for different sample types. Recovery
(mean"SD) was not significantly different between
EDTA plasma (68.1%"24.7%), heparin plasma
(52.2%"13.9%) or serum (64.5%).
Recovery following the lyophilization procedure
was also assessed in five EDTA plasma samples with
different concentrations of BNP and NT-proBNP and
measured by the common methods for these analytes
(see Table 3). Peptide concentrations were measured
in duplicate using the original EDTA plasma samples
and the lyophilized samples following reconstitution.
BNP measured with the ADVIA Centaur showed the
lowest recovery in lyophilized samples (mean recov-
ery 52%, Table 3A), while NT-proBNP measured using
ECLIA on the Elecsys platform the highest recovery
(mean recovery 91%, Table 3B). The other BNP and
NT-proBNP methods showed similar recoveries, rang-
ing on average from 62% to 67%. Only the recovery
of the ECLIA method was found to be significantly
increased compared to the other BNP and NT-proBNP
methods assays by means of one way factorial ANO-
VA (p-0.001). The recovery of the ADVIA methodwas
not significantly different when compared to other
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Table 3B Percent recovery following lyophilization in 5 plasma samples measured using the most common NT-proBNP
immunoassay methods.
Sample ECLIA Dimension
Before, After, % Before, After, %
ng/L ng/L ng/L ng/L
1 60 57 94 45.8 28 62
2 136 122 90 101 71 71
3 372 332 89 315 191 61
4 1063 951 89 946 586 62
5 4499 4248 94 4659 2929 63
Mean"SD 91.2"2.6 63.9"4.1
Before, assay performed on the original plasma sample prior to lyophilization; After, assay performed on the reconstituted
plasma following lyophilization; %, percent recovery. ECLIA, ECLIA method with Elecsys platform; Dimension, Dimension
Siemens.
Figure 1 Imprecision profiles of BNP (Part A) and NT-
proBNP (Part B) immunoassays most commonly used in the
survey.
CV values represent the mean between-laboratories varia-
bility for each method. Samples were grouped according to
concentration ranges (5 for BNP and 7 for NT-proBNP,
respectively) in order to obtain more accurate estimates of
the mean CV values.
BNP methods, as assessed by one way factorial
ANOVA, ps0.1027.
Assay methods
As shown in Table 2, BNP assay methods were more
commonly used compared with those for NT-proBNP
(53% vs. 43%). The ECLIA system for NT-proBNP
using the Elecsys and Modular platforms was the
most commonly used method, with a utilization ratio
of 41% (87% of utilization ratio among NT-proBNP
methods only).
Variability estimation
The mean total variability (i.e., including variability
among all methods and laboratories) for BNP (50.6
%CV) was significantly higher than that for NT-pro-
BNP (8.4 %CV). Furthermore, the mean variability due
to differences between-methods (46.4 %CV) included
the predominant component of total variability
observed for BNP comprising, on average, 84% of
total variability. The within-method variability showed
an average %CV of 20.2. On the contrary, within-
method variability for NT-proBNP (7.3 %CV) repre-
sented the greater part of total variability, an average
of 75%, while the between-method variability was
smaller showing a %CV of 4.1.
The imprecision profiles for the most common BNP
assays in the survey are shown in Figure 1A. Large
variability in imprecision among these methods was
found. Imprecision profiles for the most common NT-
proBNP methods are given in Figure 1B. The ECLIA
method on the Elecsys and Modular platforms
showed better performance than the Dimension
method, with a CV of -10% for the majority of the
working range of the assay.
The BNP methods showed good correlation with
correlation coefficient values ranging from Rs0.907
(correlation between ACCESS Beckman and ADVIA
Siemens) to 0.986 (correlation between ACCESS
Beckman and TRIAGE Biosite). However, a significant
difference was found between mean BNP values
measured with the Siemens ADVIA Centaur method
and those measured using the other three methods
as detected using the Scheffe´ test after ANOVA using
log-transformed data (see Figure 2A). In particular,
the ADVIA method showed marked lower values com-
pared with the AxSYM. An average difference of
–20.8%, calculated as ADVIA-AxSYM/mean value %
(p-0.0001 by Wilcoxon signed rank test), while the
ACCESS showed an average difference of –24.9%,
calculated as ADVIA-ACCCES/mean value %
(p-0.0001). In addition, the AxSYM method gave BNP
values significantly lower than those measured with
the ACCESS method; on average a difference of
766 Prontera et al.: Comparison of BNP and NT-proBNP immunoassays
Article in press - uncorrected proof
Figure 2 Box (distribution) plot of BNP (Part A) and NT-
proBNP (Part B) values measured by the most common
methods.
Data are reported as boxes indicating the 10th, 25th, 50th
(median), 75th and 90th percentiles of BNP and NT-proBNP
values measured in the 28 study samples; the outliers are
indicated as separated black circles. The asterisk (*) indicates
the level of statistical significance (p-0.0001) compared to
the ADVIA Centuar method, for BNP methods, and to the
Dimension method, for NT-proBNP methods, respectively.
–8.4% calculated as AxSYM-ACCCES/mean value %
(p-0.0005). Finally, a significant difference was found
between the mean value measured with the two
ECLIA and Dimension methods (Figure 2B), although
the difference was smaller than that seen for BNP
methods.
Evaluation of matrix effects
In order to evaluate possible matrix effects on BNP
and NT-proBNP immunoassays, some study samples
with different matrix materials were prepared and
assayed by all participant laboratories. These includ-
ed one serum sample and three heparinized plasma
samples (Table 1). The effect of sample matrix on the
total variability of BNP or NT-proBNP assays was
assessed by means of a stepwise multiple regression
analysis. This analysis included total variability as the
dependent variable and the concentration of BNP or
NT-proBNP (log-transformation of original data) and
matrix material (expressed as a dummy variable with
1 for EDTA and 2 for serum or heparin plasma) as
independent variables. The matrix material variable
showed no significant independent effect on the lin-
ear negative regression between total variability and
BNP (Rs0.445, ps0.0137) or NT-proBNP (Rs0.378,
ps0.0395).
Discussion
Theoretical limitations and aims of the study
There are some theoretical limitations concerning a
proficiency testing study for BNP and NT-proBNP
immunoassay methods. The specifications for meas-
urement of BNP recommend the use of EDTA plasma
samples, while serum is the preferred sample for NT-
proBNP (10). Furthermore, the use of EDTA plasma
samples is not recommended by the manufacturers
for some NT-proBNP immunoassays, such as the
method used on the Dimension platform (13). Follow-
ing the manufacturer’s recommendations and quality
specifications, at least two different human blood
samples should be used in a proficiency testing study
for BNP and NT-proBNP: EDTA plasma for BNP
methods, and serum for NT-proBNP. Alternatively, an
artificial material could be prepared, which is com-
mutable for all BNP and NT-proBNP immunoassay
methods. Unfortunately, to our knowledge, this type
of material is not presently available.
In order to reduce the in vitro degradation, espe-
cially for BNP, and to make the distribution and meas-
urement of blood samples easier, we decided to use
lyophilized plasma and serum samples only. It is
important to note that both plasma or serum samples
are actually used for the measurement of BNP and its
related peptides. Thus, our protocol is in accordance
with actual laboratory practice.
The primary aim of the CardioOrmocheck study is
to answer the theoretical limitations of a proficiency
study of methods for BNP and NT-proBNP that use
human plasma or serum samples. Although some dif-
ferences in the recovery of lyophilized samples were
observed between immunoassay methods (Table 3),
the results obtained in the present study are in agree-
ment with previously reported data (2, 14). This sup-
ports the suitability of this material for
between-method comparisons. The results of the
CardioOrmocheck study suggest that it is possible to
perform a reliable proficiency testing study for BNP
and NT-proBNP immunoassay methods using lyophil-
ized serum or plasma samples pools collected from
well-characterized groups of healthy subjects or car-
diac patients with or without heart failure.
Another important aim of the CardioOrmocheck
study was to mimic the actual laboratory and clinical
situations associated with measurement of BNP and
NT-proBNP. Although the results of the Cardio-
Ormocheck study are relevant to conditions seen in
Italian laboratories, some of the results of this study
may have a more general relevance, as discussed
above.
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Results and discussion
Since BNP and NT-proBNP differ in biochemical struc-
ture, molecular weight, biological activity and degra-
dation pathways (1, 2, 12), it is not surprising that BNP
and NT-proBNP assay methods may also have differ-
ent analytical characteristics and quality specifica-
tions. The biologically active peptide, BNP, shows a
shorter half-life and a more rapid degradation rate
both in vivo and in vitro than the inactive peptide, NT-
proBNP (1, 2). As a result, the biological variation of
NT-proBNP is smaller than that of BNP (15). Further-
more, BNP degradation in vitro is minimized by the
use of EDTA and/or other inhibitors of plasma prote-
ases, such as the aprotinin (2, 9–12). Indeed, quality
specifications for BNP assays recommend the use of
EDTA plasma samples (10, 11). On the contrary, pre-
vious data (16–18), as well as the results of the pres-
ent study, suggest that the NT-proBNP assay can be
performed in serum as well as EDTA or heparinized
plasma. However, possible matrix effects due to the
use of anticoagulation with EDTA or heparin should
be tested (12, 16–18). Data from this study demon-
strate that there are wide differences in analytical
characteristics among immunoassay methods. In par-
ticular, the imprecision around the cut-off values (cor-
responding to 50–100 ng/L for BNP and 100–150 ng/L
for NT-proBNP, respectively) (4, 12) showed marked
differences among methods (Figure 2). Only the two
ECLIA methods for NT-proBNP showed imprecision
profiles F10 %CV around the cut-off values (i.e.,
about 100–150 ng/L), while the Dimension method for
NT-proBNP and Access and ADVIA Siemens for BNP
(cut-off value about 50 ng/L) showed imprecision
below 20%. The other immunoassays demonstrated
even worse imprecision values.
The results of the CardioOrmocheck study confirm
that the most common BNP immunoassays are affect-
ed by large systematic differences (on average, 2.7-
fold between the Access and ADVIA Centaur
methods, Figure 2A). Agreement between NT-proBNP
methods was better (on average 1.2-fold difference
between the Dimension and ECLIA on Elecsys plat-
form methods, Figure 2B). These results were largely
expected because all the commercial NT-proBNP
methods tested in the study, the two ECLIA methods
and the Dimension method, use antibodies and stan-
dard materials from the same source (Roche Diag-
nostics), while BNP methods use different antibodies
and standard materials (2, 9–12). In particular, the
automated BNP immunoassays on the AxSYM and
ACCESS, and the POCT method on the TRIAGE Bio-
site shared similar BNP values (Figure 2A). Only the
fully-automated ADVIA Centaur method and the
immunometric assay (IRMA) by Shionogi (data not
shown), which use the same antibodies, showed sig-
nificantly lower results compared with the other
methods. The present study is in close agreement
with previous studies comparing the analytical per-
formance and diagnostic accuracy of some BNP
assays (14). The results of CardioOrmocheck study
confirm that is not reasonable to suggest similar cut-
off or decision values for all BNP assays (2, 12, 14).
Conclusions
The present study suggests that there are several the-
oretical and practical limitations to performing a pro-
ficiency study for BNP and NT-proBNP immunoassay
methods due to non-homogeneity and possible non-
commutability of human plasma and serum samples.
In addition, there are differences in recovery of ana-
lyte following lyophilization. Moreover, our data con-
firm that there are marked differences in the analytical
characteristics and measured values among the most
commonly used commercial methods for BNP and
NT-proBNP. Therefore, clinicians should carefully
evaluate results obtained by different laboratories,
especially when different methods are used. Further-
more, our findings confirm that standardization is
necessary for immunoassay methods, especially for
those that measure BNP.
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